132 related articles for article (PubMed ID: 415836)
1. Nephrotoxicity of cis-platinum (II) dichlorodiammine.
Stark JJ; Howel SB
Clin Pharmacol Ther; 1978 Apr; 23(4):461-6. PubMed ID: 415836
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1982 Jul; 31(13):2243-6. PubMed ID: 6889863
[TBL] [Abstract][Full Text] [Related]
4. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trials of WR-2721 and cis-platinum.
Glover D; Glick JH; Weiler C; Fox K; Turrisi A; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
[TBL] [Abstract][Full Text] [Related]
7. Urinary parameters predictive and electrolyte disturbances of cisplatin-induced acute renal associated with cancer as a critical target of the chemotherapeutic agent in patients with solid tumors.
Pedram B; Moghadam AT; Kamyabi-Moghaddam Z; Mavedati O; Beigi BA; Sharabiyani AK; Dezfuli AB; Khalili S; Bahrami AM; Nasoori A
Tumour Biol; 2015 Jun; 36(6):4495-500. PubMed ID: 25596088
[TBL] [Abstract][Full Text] [Related]
8. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
9. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
10. Long-term renal effect of cisplatin in man.
Brillet G; Deray G; Jacquiaud C; Mignot L; Bunker D; Meillet D; Raymond F; Jacobs C
Am J Nephrol; 1994; 14(2):81-4. PubMed ID: 8080010
[TBL] [Abstract][Full Text] [Related]
11. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity.
Verplanke AJ; Herber RF; de Wit R; Veenhof CH
Nephron; 1994; 66(3):267-72. PubMed ID: 7910667
[TBL] [Abstract][Full Text] [Related]
12. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.
Tirelli AS; Colombo N; Cavanna G; Mangioni C; Assael BM
Eur J Clin Pharmacol; 1985; 29(3):313-8. PubMed ID: 3908127
[TBL] [Abstract][Full Text] [Related]
13. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.
Hacke M; Schmoll HJ; Alt JM; Baumann K; Stolte H
Clin Physiol Biochem; 1983; 1(1):17-26. PubMed ID: 6383688
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
16. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.
Daugaard G; Rossing N; Rørth M
Cancer Chemother Pharmacol; 1988; 21(2):163-7. PubMed ID: 3280153
[TBL] [Abstract][Full Text] [Related]
17. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.
Dentino M; Luft FC; Yum MN; Williams SD; Einhorn LH
Cancer; 1978 Apr; 41(4):1274-81. PubMed ID: 638991
[TBL] [Abstract][Full Text] [Related]
18. [Ifosfamide-induced nephrotoxicity].
Rossi R; Rath B; Ullrich K; Ehrich JH
Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
[TBL] [Abstract][Full Text] [Related]
19. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats.
Martinez F; Deray G; Dubois M; Beaufils H; Jacquiaud C; Bourbouze R; Benhmida M; Jaudon MC; Jacobs C
Anticancer Drugs; 1993 Feb; 4(1):85-90. PubMed ID: 8457719
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function.
Gilbert SC; Emmett M; Menter A; Silverman A; Klintmalm G
J Am Acad Dermatol; 1989 Sep; 21(3 Pt 1):470-4. PubMed ID: 2778110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
